Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
Elizabeth Dudnik(Rabin Medical Center), Jair Bar(Tel Aviv University), Damien Urban(Tel Aviv University), Rinat Mandelboim(Rabin Medical Center), Tzippy Shochat(Rabin Medical Center), Yakir Rottenberg(Hadassah Medical Center), Alona Zer(Rambam Health Care Campus), Anastasiya Lobachov(Sheba Medical Center), Mira Wollner(Technion – Israel Institute of Technology), Ofer Rotem(Rabin Medical Center), Mor Moskovitz(Rambam Health Care Campus), Hovav Nechushtan(University Medical Center), Sameh Daher(Sheba Medical Center)
Cited by 70
Related Papers
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
|Journal of Clinical Oncology|2023|386